Jounce nix­es Redx of­fer as I/O biotech in­stead goes with Con­cen­tra Bio­sciences’ takeover bid

A mi­nor­i­ty share­hold­er has won out in the Jounce Ther­a­peu­tics takeover bat­tle, with the once-am­bi­tious im­munother­a­py biotech now choos­ing to be ac­quired by Kevin Tang’s Con­cen­tra Bio­sciences rather than fol­low through with an al­ready-an­nounced deal that would have brought the UK’s Redx on­to Nas­daq.

Via its new merg­er part­ner, Jounce is ex­pect­ed to get $1.85 per share from Con­cen­tra, which was formed by Tang Cap­i­tal Part­ners, the own­er of about 10% of Jounce shares. Two weeks ago, Con­cen­tra laid out a $1.80 per share pro­pos­al plus more for the abil­i­ty to swoop up 80% of pro­ceeds from li­cens­es of lega­cy pro­grams out of Jounce’s pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER